Some knee symptoms need other care first

Sudden or severe changes need prompt care

After a fall, get urgent help if the hurt leg won’t hold your weight. A locked knee or a visible change in shape also needs quick care. Numbness, new weakness, or lost bladder control may come from nerves. Those symptoms need a doctor without delay.

Call promptly if fever comes with a hot, puffy knee. The same advice applies after a recent procedure because infection needs fast care. Waiting to see whether ice is enough can waste needed time.

Severe wear with poor balance or a bent joint may call for surgery. Procedures made from blood or marrow haven’t been shown to rebuild that damage. Some people still need steady strength work or physical therapy. Paying for another option shouldn’t delay care that suits the knee.

If ordinary care has failed, the exam should check safety first

If ordinary care hasn’t worked, QC Kinetix offers consultations for ongoing soreness. Its regenerative treatments are clinic procedures using a prepared portion of your blood or bone marrow. At the clinic, medical providers first examine your knee and then carry out the procedure. They place the prepared portion into the knee.

Tell the provider about every health problem and medicine. The exam should check for infection, bleeding trouble, and medicines that may raise bleeding risk. Ask whom to contact if the knee swells or feels much worse. You’ll also need clear advice about movement after the procedure.

Joint preservation means trying to keep your present knee working instead of going straight to surgery. It doesn’t mean that worn cartilage will return. Some knees still need surgery or other care, and the exam should make that limit clear before you pay.

Sources

1. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

2. A randomized trial in the New England Journal of Medicine compared physical therapy against intra-articular glucocorticoid injection for knee osteoarthritis and found physical therapy produced better WOMAC outcomes at one year. When a clinic offers an injection, the comparator that matters is not 'nothing' - it is a course of supervised exercise.

   Deyle GD, et al. — Physical Therapy versus Glucocorticoid Injection for Osteoarthritis of the Knee.. The New England journal of medicine, 2020. DOI: 10.1056/NEJMoa1905877.

3. A CDC-led national public health investigation identified culture-confirmed bacterial infections in 20 patients (median age 63) across 8 US states who received umbilical cord blood-derived products marketed as stem cell treatment for pain, osteoarthritis, rheumatoid arthritis and injury. ALL BUT ONE REQUIRED HOSPITALISATION. Of unopened, undistributed product vials sampled, 65% (22 of 34) were contaminated with at least one of 16 bacterial species, mostly enteric; whole-genome sequencing linked an Arizona patient isolate to product administered in Florida.

   Hartnett KP, et al. — Investigation of Bacterial Infections Among Patients Treated With Umbilical Cord Blood-Derived Products Marketed as Stem Cell Therapies.. JAMA network open, 2021. DOI: 10.1001/jamanetworkopen.2021.28615.

4. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

   Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.

5. A randomized trial of 50 completed patients (mean age 63) compared ultrasound-guided 25% dextrose prolotherapy with intra-articular normal saline for knee OA. BOTH groups improved significantly in pain, function and knee extension at every follow-up (p<0.001), and prolotherapy was neither statistically nor clinically superior to saline. Adverse events were limited to injection-site pain and bruising resolving by week 4.

   Teymouri A, et al. — Comparison of the efficacy of ultrasound-guided dextrose 25% hypertonic prolotherapy and intra-articular normal saline injection on pain, functional limitation, and range of motion in patients with knee osteoarthritis; a randomized controlled trial.. BMC musculoskeletal disorders, 2025. DOI: 10.1186/s12891-025-08580-5.